Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 37-40

  Desai, Harit ^a   Aronow, Wilbert S ^a   Ahn, Chul ^b   Tsai, Fausan S ^a   Lai, Hoang M ^a   Gandhi, Kaushang ^a   Amin, Harshad ^a   Frishman, William H ^a   Kalapatapu, Kumar ^a   Cohen, Martin ^a   Sorbera, Carmine ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cardiac resynchronization therapy; Cardioverter defibrillator shocks; Heart failure; Implantable cardioverter defibrillator; Mortality

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOTALOL;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DEFIBRILLATOR; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SHOCK; SMOKING;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOPULMONARY RESUSCITATION; DEFIBRILLATORS, IMPLANTABLE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 76649112719     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409351408     Document Type: Article

References (9)

1. Bristow MR, Saxon LA, Boehmer J., et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 ; 350 (21). 2140-2150.
2. Aronow WS, Ahn C., Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol. 2000 ; 85 (11). 1382-1384.
3. Goldenberg I., Moss AJ, McNitt S., et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2006 ; 17 (9). 931-936.
4. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000 ; 36 (3). 766-772.
5. Mitchell LB, Powell JL, Gillis AM, Kehl V., Hallstrom AP, and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003 ; 42 (1). 81-87.
6. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol. 2005 ; 95 (4). 490-491.
7. Desai H., Aronow WS, Tsai FS, et al. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter- defibrillator therapy. J Cardiovasc Pharmacol Ther. 2009 ; 14 (3). 176-179.
8. Vyas AK, Guo H., Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter automatic Defibrillator Implantation trial (MADIT)-II. J Am Coll Cardiol. 2006 ; 47 (4). 769-773.
9. Lai HM, Aronow WS, Kruger A., et al. and the MADIT-II Research Group. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2008 ; 102 (1). 77-78.